Nordson Corporation Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Machinery | Market Cap: ₹16.1K Cr
- Nordson expects continued above-market organic growth driven by accelerating demand in key end markets such as semiconductor, electronics, and medical. - Nordson expects to continue returning to normalized growth rates in medical segment, targeting 6% to 8% growth.
From Nordson Corporation's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹288.12
Market Cap
₹16.1K Cr
P/E Ratio
30.8
Revenue Rank
Margin Rank
How does Nordson Corporation rank in Machinery?
Compare Nordson Corporation against every Machinery company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →Nordson expects continued above-market organic growth driven by accelerating demand in key end markets such as semiconductor, electronics, and medical.
- →Full year sales guidance increased to a range of $2.930 billion to $3.010 billion, with high confidence in the midpoint.
- →Strong backlog up 18%, broad-based across all segments, signaling sustained order momentum.
- →The Advanced Technology Solutions (ATS) segment shows notable strength with double-digit backlog growth and ongoing strength in semiconductor demand.
- →Medical segment targeting normalized growth rates of 6-8%, supported by order entry and backlog build-up.
- →Industrial Precision segment growing at 4% organically, with improving trends in plastics and coatings.
- →Continued growth expected from precision agriculture after recent acquisition of CapstanAG.
- →Confidence maintained despite macroeconomic uncertainties, with prudent outlook for potential raw material or customer pullback risks.
📈 Profitability & Margins
Rank 3- →Nordson expects to continue returning to normalized growth rates in medical segment, targeting 6% to 8% growth.
- →Industrial Precision Solutions shows improving demand and 4% organic growth, with best-in-class margins targeted.
- →Advanced Technology Solutions (ATS) segment backlog up 18% with strong momentum, indicating durable demand.
- →Incremental EBITDA improved in the quarter and expected to return to normal incremental performance as the year progresses.
- →Adjusted earnings per share for Q2 rose 18% YoY to a record $2.86, exceeding guidance by $0.06.
- →Full-year adjusted effective tax rate is expected within 18%-19%, slightly better than prior guidance, supporting sustainable profitability.
- →Strong free cash flow ($170 million) and improved leverage ratio (1.9x net debt to EBITDA) provide capacity for disciplined strategic investments and shareholder returns.
- →No fundamental change in backlog timing, with most backlog converting within 6 months, supporting near-term earnings visibility.
- →The company remains cautiously optimistic, watching macro uncertainties but confident in underlying demand drivers.
🏗️ Capital Expenditure Plans
Yes- →$10 million invested in capital projects during the quarter to support current and future organic growth (Page 3).
- →Strategic acquisition of CapstanAG, a precision agriculture technology leader in North America, to grow precision agriculture portfolio and expand product offerings (Pages 2 and 4).
- →Ongoing M&A activity with a robust pipeline, focused on disciplined acquisitions meeting strategic and financial criteria, especially in medical, test and inspection, and bolt-on technology for existing businesses (Page 9).
- →$900 million capacity remaining for acquisitions, indicating future potential strategic investments (Page 9).
- →Capital allocation balances growth investment, shareholder returns, and debt reduction, supporting sustainable franchise growth (Page 3).
💰 Fundraising & Capital Structure
No information- →There is no indication of any new fundraising through debt or equity in the transcript.
- →The company reported strong cash flow generation ($170 million free cash flow in Q2) and significant financial capacity (about $900 million in capacity remaining).
- →Net debt was approximately $1.8 billion with a leverage ratio of 1.9x, which is below the company's long-term target range.
- →The company has been actively managing debt, including reducing net debt by $93 million in the quarter.
- →Focus remains on disciplined M&A activity funded through existing cash flow and capacity.
- →No explicit plans or statements about upcoming equity raises or additional debt issuance were mentioned.
📋 Order Book & Pipeline
Yes- →Backlog is up 18%, with all segments contributing to strong order momentum (Page 9).
- →ATS segment shows robust backlog growth, likely in double digits, contributing significantly to overall backlog increase (Page 9).
- →Majority of backlog converts within 6 months; some portion extends into 2027 but remains a minority (Page 8).
- →Lead times have improved from 16-18 weeks to less than 7-8 weeks, with some systems shipping within the quarter (Page 10).
- →Order entry and backlog buildup in Medical segment support confidence in returning to normalized growth (Page 5).
- →Strong order momentum across all segments, providing high confidence at the midpoint of sales guidance (Page 10).
- →No fundamental change in delivery requests; order lead times remain typical without longer-term order hoarding (Page 11).
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Machinery this season
- SPX Technologies, Inc. (Q2 FY26)
SPX Technologies, Inc. Q2 FY26 quarterly results analysis. Data center segment projected to grow from ~$200 million to $350 million in 2026, with potential capa
- Pentair plc (Q2 FY26)
Pentair plc Q2 FY26 quarterly results analysis. Pentair expects total sales in 2026 to increase approximately 2% to 4%. Market Cap $11,527, P/E 18.5. AI-powered
- Stanley Black & Decker, Inc. (Q2 FY26)
Stanley Black & Decker, Inc. Q2 FY26 quarterly results analysis. Tools & Outdoor segment expects low single-digit organic revenue growth in 2026, led by market
- Graco Inc. (Q2 FY26)
Graco Inc. Q2 FY26 quarterly results analysis. Graco forecasts low single-digit organic revenue growth on a constant currency basis for 2026. Market Cap $12,584
Frequently Asked Questions
What were Nordson Corporation Q2 FY26 results?
- Nordson expects continued above-market organic growth driven by accelerating demand in key end markets such as semiconductor, electronics, and medical. - Nordson expects to continue returning to normalized growth rates in medical segment, targeting 6% to 8% growth.
What is Nordson Corporation share price analysis?
Nordson Corporation currently shows a below-average growth signal. The stock trades at a P/E of 30.8 with a market cap of $16,053. Investors should review the full earnings analysis for detailed insights.
Is Nordson Corporation planning capital expenditure?
- $10 million invested in capital projects during the quarter to support current and future organic growth (Page 3).
Keep Nordson Corporation on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.